<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2013</study_start_year><condition>Unresectable Metastatic Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><condition>Cancer</condition><disease>Unresectable Metastatic Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><disease>Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2140917</full_dataset_link><location>France</location><study_start_month>5</study_start_month><keyword>OPTIMOX</keyword><keyword>Colorectal</keyword><keyword>Unresectable</keyword><keyword>Metastatic</keyword><keyword>Aflibercept</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer</name><description>Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.</description><dates><creation>2013-05-15</creation></dates><accession>2140917</accession><cross_references><ClinicalTrials___gov>NCT01802684</ClinicalTrials___gov><EU Clinical Trials Register>2012-003521-25</EU Clinical Trials Register></cross_references></HashMap>